P4HB and cancer: P4HB was reported to be amplified with a high frequency (9.09%) in our ESCC cases (Cheng et al., 2016; Song et al., 2014) and multiple types of cancer (Fig. S3A), and its overexpression could predict poor survival of patients with ESCC (Fig. S3B and C).